Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
Half-life ~6 days (~144 h), enabling once-weekly SC dosing (stated in peer-reviewed phase 2a paper). Steady state ~4-5 weeks.
Model a dosing schedule →Phase 2 obesity trial: 1, 4, 8, or 12 mg once weekly with dose escalation every 4 weeks (starting doses 2 or 4 mg for higher target arms). Investigational, not an approved dosing regimen.
Published phase 2 randomized trials (obesity, MASLD); no regulatory label. Molecular weight not found in an allowed primary source.
Investigational; no boxed warning issued (no label). Trial adverse events predominantly gastrointestinal (nausea, diarrhea, vomiting), dose-dependent. Glucagon-agonist component may raise heart rate. Not for clinical dosing decisions.